Forma Therapeutics and Boehringer Ingelheim Partner to Target Oncology-Relevant Protein-Protein Interactions
By Heather Cartwright
Pharma Deals Review: Vol 2012 Issue 2 (Table of Contents)
Published: 10 Feb-2012
DOI: 10.3833/pdr.v2012.i2.1677 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
Forma Therapeutics has landed a 4-year cancer drug discovery deal with Boehringer Ingelheim that is potentially worth up to US$815 M to discover small molecule therapeutics against oncology-relevant protein-protein interactions...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS